Literature DB >> 18051819

[Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy].

Daisuke Watanabe1.   

Abstract

UNLABELLED: Although retinal neovascularization in proliferative diabetic retinopathy(PDR) is a major cause of legal blindness, its mechanism is not fully understood. In this study, we focused on the angiogenic activity of erythropoietin (Epo) and evaluated its potential role in treating retinal angiogenesis in PDR.
METHODS: We measured Epo and vascular endothelial growth factor (VEGF) levels in the vitreous fluids of 73 PDR patients and 71 nondiabetic (NDM) patients. We evaluated Epo expression and regulation in retinal neovascularization with soluble Epo receptor.
RESULTS: The vitreous Epo level was significantly higher in patients with PDR than in NDM patients. Multivariate logistic-regression analyses indicated that Epo and VEGF were independently associated with PDR and that Epo was more strongly associated with PDR than VEGF was. The blockade of Epo inhibited retinal neovascularization in vitro and in vivo.
CONCLUSIONS: Our data suggest that Epo is a potent angiogenic factor that acts independently of VEGF during retinal angiogenesis in PDR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18051819

Source DB:  PubMed          Journal:  Nippon Ganka Gakkai Zasshi        ISSN: 0029-0203


  5 in total

1.  Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina.

Authors:  Q Wang; F Pfister; A Dorn-Beineke; F vom Hagen; J Lin; Y Feng; H P Hammes
Journal:  Diabetologia       Date:  2010-03-26       Impact factor: 10.122

Review 2.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

Review 3.  MicroRNA signature and function in retinal neovascularization.

Authors:  Saloni Agrawal; Brahim Chaqour
Journal:  World J Biol Chem       Date:  2014-02-26

4.  Erythropoietin levels in aqueous humor of patients with glaucoma.

Authors:  Nader Nassiri; Nariman Nassiri; Mercede Majdi; Hadi Z Mehrjardi; Yadollah Shakiba; Maryam Haghnegahdar; Amir Behzad Heidari; Ali R Djalilian; Mahroo Mirahmadian
Journal:  Mol Vis       Date:  2012-07-18       Impact factor: 2.367

5.  Effects of quercetin on the expression of MCP-1, MMP-9 and VEGF in rats with diabetic retinopathy.

Authors:  Bin Chen; Tao He; Yiqiao Xing; Ting Cao
Journal:  Exp Ther Med       Date:  2017-10-10       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.